Eisai Joins WIPO Sponsored Global Consortium for Neglected Tropical Disease Research and Development

October 26, 2011, Tokyo, Japan -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, ("Eisai") announced today that it has joined WIPO Re:Search, a new global consortium established on October 26 (local time in Geneva, Switzerland) and sponsored by the World Intellectual Property Organization (WIPO) with the aim of supporting research and development for neglected tropical diseases. Eisai is the only Japanese pharmaceutical company to become a member of the consortium.

Click here to view the entire press release.

Type Press Release

Date Released October 26, 2011

Jun 1, 2020

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the availability of DAYVIGO™ (lemborexant) CIV for the treatment of adults with insomnia, characterized by...

May 29, 2020

Eisai today announced updated results from ENHANCE 1, a Phase 1b/2 study exploring the investigational combination of eribulin plus pembrolizumab in patients with metastatic triple-negative breast...

May 28, 2020

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 28, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new data from analyses of two trials...

Alerts - Release page
* Required Fields